Literature DB >> 26631763

Malleus to Stapes Bone Cement Rebridging Ossiculoplasty: Why Don't We Perform Frequently?

Deniz Tuna Edizer1, Yusuf Muhammed Durna2, Bahtiyar Hamit2, Hasan Demirhan2, Ozgur Yigit2.   

Abstract

OBJECTIVE: To evaluate the effectiveness of malleus to stapes bone cement rebridging (MS-BCR) for Austin Kartush group A ossicular defects and compare the audiological results with incus interposition (IP) and incus to stapes bone cement rebridging (IS-BCR).
METHODS: Patients for whom type 2 tympanoplasty had been performed in a tertiary referral center were examined. Revision cases and those with graft failure were excluded. Three treatment groups were IS-BCR, IP, and MS-BCR. Preoperative and postoperative audiological results were compared.
RESULTS: A total of 92 patients were enrolled. The IS-BCR was performed in 42 (45.65%), IP in 18 (19.56%), and MS-BCR in 32 (34.78%) patients. Postoperative mean air bone gap was 20.1 ± 9.8 dB HL and did not differ significantly between the groups (P = .271). Postoperative mean air bone gap less than 20 dB HL was achieved in 23 (54.7%) patients in IS-BCR, 10 (55.5%) patients in IP group, and 24 (75%) patients in MS-BCR group (P = .06). Mean closure in air bone gap was 14.0 ± 11.6 dB HL. The changes in mean and frequency-specific air bone gap were not significantly different between treatment groups (P > .05).
CONCLUSION: Malleus to stapes bone cement rebridging may provide hearing results comparable to IS-BCR and IP.
© The Author(s) 2015.

Entities:  

Keywords:  chronic middle ear disease; chronic otitis media; functional measures; middle ear; ossiculoplasty

Mesh:

Substances:

Year:  2015        PMID: 26631763     DOI: 10.1177/0003489415618678

Source DB:  PubMed          Journal:  Ann Otol Rhinol Laryngol        ISSN: 0003-4894            Impact factor:   1.547


  1 in total

1.  Stapes stabilizing cartilage graft.

Authors:  Ibrahim Erdim; Emrah Sapmaz
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-11-12       Impact factor: 2.503

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.